印度正调查与疫苗相关血栓个案 单日增近13.2万宗确诊连续三日破顶
欧洲监管机构周三(7日)指出发现阿斯利康疫苗与罕有血栓或有潜在关系,并补充指疫苗的优点仍大於风险,但已引起多国关注。据印度报章《Mint》引述消息称,印度政府专家团队正审核与当地采用两款新冠疫苗相关的任何血栓个案,即使情况仅温和。印度现批准使用阿斯利康(AZN.US)疫苗及由当地生科企业Bharat Biotech开发的COVAXIN疫苗。消息补充,下周料准备好报告。
印度今日(9日)新增近13.2万宗新冠确诊,连续三日创新高。死亡增870宗,累计16.7万人病殁。该国累计1,306万宗确诊,属全球第三高,仅次於美国及巴西。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.